

Enhancing Sight. Enhancing Lives.



Who We Are & What We Do

Alcon, the second largest division of Novartis, is the global leader in eye care. Our mission is to provide innovative products that enhance quality of life by helping people see better. We accomplish our mission by giving eye care professionals the products and tools they need to deliver the best treatment outcomes to their patients.

We were founded in 1945 as a small ophthalmic shop in Fort Worth, Texas. Over the past 70 years, we have become the world's leading eye care company through a combination of innovative research and development, strategic acquisitions, and partnerships with renowned third-party organizations. Today, we proudly reach more than 90% of the globe – operating in more than 75 countries, serving 180 markets and employing more than 25,000 people.

Our three businesses – surgical, pharmaceutical and vision care – offer the widest spectrum of industry leading products that address the full life cycle of eye care needs. We treat all parts of the eye through a comprehensive line of high-quality ophthalmic surgical and pharmaceutical products, and a broad portfolio of contact lenses and lens care products.



Increasing Access to Eye Care in a Changing Environment

Patients are at the center of everything we do at Alcon. Our consistent focus on patients drives our commitment to providing innovative and high-quality products that enhance people's sight and lives.

We know that eye care needs are rapidly evolving. The aging population continues to grow and requires enhanced medical needs; emerging markets are demanding greater access to quality care; and a changing communications landscape is empowering patients to connect with one another and educate themselves as never before.

We believe that everyone should have the best possible vision throughout their lives. Our businesses are well positioned to take advantage of this changing global landscape, address preventable blindness and create a foundation to deliver world-class eye care for future generations.

Alcon





Our Unmatched R&D Commitment

Alcon invests more than \$1 billion annually in research and development to deliver innovations that solve unmet medical needs. Our commitment to research and development is unparalleled in the private sector.

Our global research and development team of more than 2,000 highly skilled individuals is developing a full range of eye care products and solutions across our three businesses to treat cataracts, glaucoma, retinal diseases, age-related macular degeneration (AMD), dry eye, infection, inflammation, ocular allergies, refractive errors and other serious ocular issues. Our product pipeline is fueled by in-house development, partnerships with leading institutions, acquisitions and in-licensing.

Our Commitment to Corporate Social Responsibility

particularly in countries with insufficient access to eye care.



orbis

We believe everyone deserves access to quality eye care regardless of economic status or where they live in the world. Since 1964, Alcon has delivered on this commitment through Foundation giving, in-kind product donations, partnerships and community volunteer efforts.

Our dedication to preserving, restoring and enhancing sight spans the globe. Our corporate giving efforts help eliminate barriers and reduce the incidence of preventable blindness and visual impairment,

OPTOMETRYCIVINGSIGHT



VisionSpring

Alcon supports more than 600 medical missions in more than 80 countries to bring eye care to places in which services and treatments are not yet available, train local physicians to perform state-of-the-art surgery, provide sustainable eye care, and restore vision in more than 40,000 people each year.



Our Focus on Eye Care Education

Alcon values eye care professionals as trusted partners in advancing our mission of improving quality of life by helping people see better.

The Alcon Medical Education Department supports educational initiatives, which offer comprehensive, high-quality information on medical and surgical management for effective treatments of ophthalmic, otic, and nasal conditions and diseases.

The Independent Medical Education Grant Office funds educational initiatives for health care professionals to promote scientific knowledge, medical advancement and the delivery of effective health care.

Since 2011, Alcon has invested more than US\$27 MM to support nearly 1,200 independent medical education grants that reached more than 800,000 eye care practitioners.